Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/ or PI3K

Details for Australian Patent Application No. 2008273891 (hide)

Owner AstraZeneca AB

Inventors Pike, Kurt Gordon

Agent Davies Collison Cave

Pub. Number AU-B-2008273891

PCT Pub. Number WO2009/007750

Priority 60/948,539 09.07.07 US

Filing date 8 July 2008

Wipo publication date 15 January 2009

Acceptance publication date 12 January 2012

International Classifications

C07D 239/42 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

A61K 31/505 (2006.01) - Pyrimidines

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 11/00 (2006.01) Drugs for disorders of the respiratory system

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

14 January 2010 PCT application entered the National Phase

  PCT publication WO2009/007750 Priority application(s): WO2009/007750

12 January 2012 Application Accepted

  Published as AU-B-2008273891

10 May 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008273892-Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases

2008273889-Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases